CN109528720B - Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 - Google Patents
Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 Download PDFInfo
- Publication number
- CN109528720B CN109528720B CN201910016384.9A CN201910016384A CN109528720B CN 109528720 B CN109528720 B CN 109528720B CN 201910016384 A CN201910016384 A CN 201910016384A CN 109528720 B CN109528720 B CN 109528720B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- mice
- tumor
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 12
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 12
- 238000002360 preparation method Methods 0.000 title description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 19
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 72
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 25
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 25
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 13
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 abstract description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 11
- 239000012826 P38 inhibitor Substances 0.000 abstract description 11
- 201000005202 lung cancer Diseases 0.000 abstract description 10
- 208000020816 lung neoplasm Diseases 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 5
- 230000003907 kidney function Effects 0.000 abstract description 4
- 230000003908 liver function Effects 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 102000000585 Interleukin-9 Human genes 0.000 description 17
- 230000010287 polarization Effects 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 12
- 101150064015 FAS gene Proteins 0.000 description 11
- 230000034964 establishment of cell polarity Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000010682 Interleukin-9 Receptors Human genes 0.000 description 2
- 108010038414 Interleukin-9 Receptors Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 108010041980 MAP-kinase-activated kinase 3 Proteins 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101100179587 Mus musculus Il9r gene Proteins 0.000 description 1
- 101001055215 Mus musculus Interleukin-9 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010019759 OVA 323-339 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910912293.3A CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
CN201910016384.9A CN109528720B (zh) | 2019-01-08 | 2019-01-08 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910016384.9A CN109528720B (zh) | 2019-01-08 | 2019-01-08 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910912293.3A Division CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109528720A CN109528720A (zh) | 2019-03-29 |
CN109528720B true CN109528720B (zh) | 2021-03-30 |
Family
ID=65834373
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910016384.9A Active CN109528720B (zh) | 2019-01-08 | 2019-01-08 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN201910912293.3A Active CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910912293.3A Active CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN109528720B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118234516A (zh) * | 2021-11-22 | 2024-06-21 | 宁波康柏睿格医药科技有限公司 | Rip2抑制剂联合化疗药物的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458841A (zh) * | 2000-07-17 | 2003-11-26 | 克里斯蒂安·西蒙 | 应用基质金属蛋白酶抑制剂治疗癌症 |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
WO2013169479A1 (en) * | 2012-05-11 | 2013-11-14 | Massachusetts Institute Of Technology | Compositions and methods of treatment of drug resistant cancers |
WO2017117182A1 (en) * | 2015-12-29 | 2017-07-06 | Board Of Regents, The University Of Texas System | Inhibition of p38 mapk for the treatment of cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038143A2 (en) * | 2000-11-07 | 2002-05-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation |
-
2019
- 2019-01-08 CN CN201910016384.9A patent/CN109528720B/zh active Active
- 2019-01-08 CN CN201910912293.3A patent/CN110624108B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458841A (zh) * | 2000-07-17 | 2003-11-26 | 克里斯蒂安·西蒙 | 应用基质金属蛋白酶抑制剂治疗癌症 |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
WO2013169479A1 (en) * | 2012-05-11 | 2013-11-14 | Massachusetts Institute Of Technology | Compositions and methods of treatment of drug resistant cancers |
WO2017117182A1 (en) * | 2015-12-29 | 2017-07-06 | Board Of Regents, The University Of Texas System | Inhibition of p38 mapk for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
CN109528720A (zh) | 2019-03-29 |
CN110624108A (zh) | 2019-12-31 |
CN110624108B (zh) | 2022-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maradana et al. | Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis | |
KR20160093012A (ko) | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 | |
WO2019083971A1 (en) | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | |
CN102223896A (zh) | 抗-β-2-微球蛋白试剂及其用途 | |
WO2012075291A1 (en) | Compositions and methods for treating foxp3+ treg related diseases | |
EP3915585A1 (en) | Therapeutic combinations comprising agonists of ferroptosis for treating proliferative disorders | |
JP7235259B2 (ja) | Gvhd又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節 | |
US20110184045A1 (en) | Silencng and rig-i activation by dual function oligonucleotides | |
KR102377702B1 (ko) | Syt11 억제제를 유효성분으로 포함하는 위암 치료용 조성물 | |
Hantel et al. | TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors | |
CN109528720B (zh) | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 | |
WO2020146345A1 (en) | Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy | |
US20170369841A1 (en) | Method for modifying t cell population | |
CN111166867B (zh) | Pd-1泛素化激动剂的功能与用途 | |
Yuan et al. | Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer | |
KR101384360B1 (ko) | Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 | |
US20230233474A1 (en) | Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer | |
US9752145B2 (en) | Compositions and methods for reducing C/EBP homologous protein activity in myeloid-derived suppressor cells | |
Le et al. | NF-κB-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations | |
CN108079301B (zh) | 减少cxcl13蛋白活性或表达量的活性物质在制备治疗恶性肿瘤转移药物中的用途 | |
Yuan et al. | Inhibition of interferon regulatory factor 4 orchestrates T cell dysfunction, extending mouse cardiac allograft survival | |
CN106554962B (zh) | 过表达gpr160的癌症的预防、诊断和治疗 | |
WO2019136621A1 (en) | Nr4a1 as key mediator of t cell tolerance | |
CN114028398B (zh) | 一种组蛋白去乙酰化酶hdac11抑制剂在制备防治真菌感染药物中的应用 | |
CN108159419B (zh) | 诱导irf8表达的物质在制备治疗肝癌的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Cai Zhijian Inventor after: Wang Jianli Inventor after: Shen Yingying Inventor after: Song Zhengbo Inventor after: Ma Zeyu Inventor after: Zhang Bei Inventor after: Lu Chaojie Inventor before: Wang Jianli Inventor before: Cai Zhijian Inventor before: Shen Yingying Inventor before: Song Zhengbo Inventor before: Ma Zeyu Inventor before: Zhang Bei Inventor before: Lu Chaojie |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |